{"totalCount":2,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT05544552","orgStudyIdInfo":{"id":"TYR300-101"},"organization":{"fullName":"Tyra Biosciences, Inc","class":"INDUSTRY"},"briefTitle":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","officialTitle":"A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)","acronym":"SURF301"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-11-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-09-06","studyFirstSubmitQcDate":"2022-09-15","studyFirstPostDateStruct":{"date":"2022-09-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-08","lastUpdatePostDateStruct":{"date":"2026-01-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Tyra Biosciences, Inc","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.","detailedDescription":"This is a single arm, multi-part, phase 1/2 global trial studying TYRA-300, a novel, potent fibroblast growth factor receptor (FGFR) 3-selective tyrosine kinase inhibitor, in advanced/metastatic urothelial carcinoma of the bladder and urinary tract, that contain activating gene alterations of FGFR3. Phase 1 is a dose-escalation study to evaluate the safety, tolerability, and PK of TYRA-300 to determine the optimal and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Phase 2 will evaluate the preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors."},"conditionsModule":{"conditions":["Locally Advanced Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Solid Tumor","Urothelial Carcinoma","Solid Tumor, Adult","Bladder Cancer","Non-muscle-invasive Bladder Cancer","FGFR3 Gene Mutation","FGFR3 Gene Alteration","Advanced Solid Tumor","Advanced Urothelial Carcinoma","Urinary Tract Cancer","Urinary Tract Tumor","Urinary Tract Carcinoma"],"keywords":["bladder","FGFR3 gene activation","FGFR3 gene alterations","FGFR3 gene fusion/rearrangement","FGFR3 gene mutation","FGFR3 gene translocation","FGFR3 positive","Fibroblast growth factor receptor 3 (FGFR3)","Fibroblast growth factor receptor 3 alterations","locally advanced cancer","metastatic cancer","solid tumors","urothelial cancer","urothelial carcinoma","Urinary tract cancer","Urinary tract tumor","Urinary tract carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":310,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Phase 1 Part A - dose escalation","type":"EXPERIMENTAL","description":"TYRA-300 taken once daily by mouth in 28-day cycles starting at 10 mg daily.","interventionNames":["Drug: TYRA-300"]},{"label":"Phase 1 Part B - dose expansion","type":"EXPERIMENTAL","description":"TYRA-300 taken once or twice daily by mouth in 28-day cycles.","interventionNames":["Drug: TYRA-300"]},{"label":"Phase 2","type":"EXPERIMENTAL","description":"TYRA-300 taken once or twice daily by mouth in 28-day cycles at doses determined during Phase 1.","interventionNames":["Drug: TYRA-300"]}],"interventions":[{"type":"DRUG","name":"TYRA-300","description":"TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.","armGroupLabels":["Phase 1 Part A - dose escalation","Phase 1 Part B - dose expansion","Phase 2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Phase 1 Part A: To determine the maximum tolerated doses (MTD).","timeFrame":"Initiation of study treatment through 28 days."},{"measure":"Phase 1 Part B: To determine the recommended Phase 2 dose (R2PD).","timeFrame":"Initiation of study treatment through 28 days (up to approximately 18 months)."},{"measure":"Phase 2: Overall Response Rate (ORR), defined by RECIST v1.1.","timeFrame":"Initiation of study treatment until disease progression, death, unacceptable toxicity, or withdrawal (up to 2 years)."}],"secondaryOutcomes":[{"measure":"Number of participants with adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability.","timeFrame":"Initiation of study treatment through 28-days post treatment (up to 2 years)."},{"measure":"Frequency in changes in laboratory parameters and physical signs of toxicity.","timeFrame":"Initiation of study treatment through 28-days post treatment (up to 2 years)."},{"measure":"Pharmacokinetics: maximum plasma concentration (Cmax).","timeFrame":"Initiation of study treatment through Cycle 3 Day 1 (each cycle is 28 days)."},{"measure":"Pharmacokinetics: time to reach maximum plasma concentration (Tmax).","timeFrame":"Initiation of study treatment through Cycle 3 Day 1(each cycle is 28 days)."},{"measure":"Pharmacokinetics: area under the plasma concentration-time curve (AUC).","timeFrame":"Initiation of study treatment through Cycle 3 Day 1 (each cycle is 28 days)."},{"measure":"Pharmacokinetics: half-life of TYRA-300 (t1/2).","timeFrame":"Initiation of study treatment through Cycle 3 Day 1 (each cycle is 28 days)."},{"measure":"ORR is defined as the proportion of participants with complete response (CR) or partial response (PR) as determined by the investigator using RECIST V1.1.","timeFrame":"From enrollment, every 8 or 12 weeks (up to 2 years)."},{"measure":"Duration of response will be defined as the time from the initial CR or PR to the time of relapse or death, whichever occurs first among participant with an objective response.","timeFrame":"From enrollment, every 8 or 12 weeks (up to 5 years)."},{"measure":"Disease control rate is defined as the proportion of participants having a CR, PR or stable disease (SD) for >12 weeks.","timeFrame":"From enrollment up to 5 years."},{"measure":"Time to response is defined as time to first CR or PR that is subsequently confirmed according to RECIST v1.1.","timeFrame":"Up to 5 years."},{"measure":"Progression-free survival is defined as the time from the date of first study drug administration to the earliest date of documented disease progression or death.","timeFrame":"From the date of the first dose of study drug until disease progression or death as assessed up to the last efficacy assessment for disease progression (up to 5 years)]."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPhase 1 Part A and Part B\n\n* Men and women 18 years of age or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.\n* Histologically confirmed advanced solid tumor who have exhausted standard therapeutic options.\n* Evaluable (Part A) or measurable (Part B) disease according to RECIST v1.1.\n* Histologically confirmed advanced solid tumor with an eligible FGFR3 gene mutation or fusion (Part B).\n\nPhase 2\n\n* Men and women 18 years of age or older.\n* ECOG performance status of 0-2 or Karnofsky Performance Scale (KPS) \\>70.\n* At least 1 measurable lesion by RECIST v1.1.\n* Histologically confirmed locally advanced/metastatic tumor in one of the following categories:\n\n  * Urothelial carcinoma with an eligible FGFR3 gene mutation or rearrangement who have progressed on a prior FGFR inhibitor and presence of a resistance mutation or other kinase domain mutation.\n  * Urothelial carcinoma with an eligible FGFR3 gene mutation or rearrangement who has not received a prior FGFR inhibitor.\n  * Any solid tumor with an eligible FGFR3 gene mutation or rearrangement.\n\nExclusion Criteria (All Phases):\n\n* Has a serum phosphorus level \\> upper limit of normal (ULN) during screening that remains \\>ULN despite medical management.\n* Any ocular condition likely to increase the risk of eye toxicity.\n* History of or current uncontrolled cardiovascular disease.\n* Active, symptomatic, or untreated brain metastases.\n* Gastrointestinal disorders that will affect oral administration or absorption of TYRA-300.\n* Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Doug Warner","affiliation":"Tyra Biosciences, Inc","role":"STUDY_CHAIR"}],"locations":[{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"UMass Memorial Medical Center","city":"Worchester","state":"Massachusetts","zip":"01655","country":"United States"},{"facility":"Memorial Sloan Kettering Cancer Center (MSKCC)","city":"New York","state":"New York","zip":"10021","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Duke Cancer Institute (DCI) - Duke Cancer Center","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Cleveland Clinic - Main Campus","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Seattle Cancer Care Alliance (SCCA) - South Lake Union","city":"Seattle","state":"Washington","zip":"98109","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Macquarie University","city":"Macquarie Park","state":"New South Wales","zip":"2109","country":"Australia","geoPoint":{"lat":-33.78105,"lon":151.12757}},{"facility":"Tasman Oncology","city":"Southport","state":"Queensland","zip":"4215","country":"Australia","geoPoint":{"lat":-27.96724,"lon":153.39796}},{"facility":"Princess Alexandra Hospital","city":"Woolloongabba","state":"Queensland","zip":"4102","country":"Australia","geoPoint":{"lat":-27.48855,"lon":153.03655}},{"facility":"Austin Health","city":"Heidelberg","state":"Victoria","zip":"3084","country":"Australia","geoPoint":{"lat":-37.75,"lon":145.06667}},{"facility":"Peter MacCallum Cancer Research Unit","city":"Melbourne","state":"Victoria","zip":"3000","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Linear Clinical Research Limited","city":"Nedlands","state":"Washington","zip":"6009","country":"Australia","geoPoint":{"lat":-31.98184,"lon":115.8073}},{"facility":"Institut de Cancerologie de L'Ouest (ICO)","city":"Saint-Herblain","zip":"44805","country":"France","geoPoint":{"lat":47.21154,"lon":-1.651}},{"facility":"Institut Claudius Regaud, IUCT-Oncopole","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Gustave Roussy (Institut de Cancerologie Gustave-Roussy)","city":"Villejuif","zip":"94805","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"NEXT Barcelona - Hospital Quironsalud Barcelona","city":"Barcelona","zip":"08023","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Vall d'Hebron Institut d'Oncologia (VHIO)","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"NEXT Madrid - Hospital Universitario Quironsalud Madrid","city":"Madrid","zip":"28223","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D002295","term":"Carcinoma, Transitional Cell"},{"id":"D001749","term":"Urinary Bladder Neoplasms"},{"id":"D000093284","term":"Non-Muscle Invasive Bladder Neoplasms"},{"id":"D014571","term":"Urologic Neoplasms"},{"id":"D009362","term":"Neoplasm Metastasis"}],"ancestors":[{"id":"D002277","term":"Carcinoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D001745","term":"Urinary Bladder Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D009385","term":"Neoplastic Processes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06160752","orgStudyIdInfo":{"id":"TYR200-101"},"organization":{"fullName":"Tyra Biosciences, Inc","class":"INDUSTRY"},"briefTitle":"Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations","officialTitle":"A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors With Activating FGFR2 Gene Alterations (SURF-201)","acronym":"SURF201"},"statusModule":{"statusVerifiedDate":"2024-10","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-11-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-09","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-11-29","studyFirstSubmitQcDate":"2023-11-29","studyFirstPostDateStruct":{"date":"2023-12-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-10-01","lastUpdatePostDateStruct":{"date":"2024-10-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Tyra Biosciences, Inc","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.","detailedDescription":"This is a single arm, multi-part, phase 1 clinical trial studying TYRA-200, a novel, potent fibroblast growth factor receptor (FGFR) 1/2/3 tyrosine kinase inhibitor, in unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors with activating alterations in FGFR2. Part A is a dose escalation study in participants with any advanced solid tumor with FGFR/FGF pathway alterations who have exhausted approved standard therapies. Part A will evaluate the safety, tolerability, and PK of TYRA-200 to determine the optimal and maximum tolerated dose (MTD). Part B will evaluate the preliminary antitumor activity of TYRA-200 in participants with unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma who have previously received an FGFR inhibitor and have FGFR2 kinase-domain mutations resistant to other FGFR inhibitors."},"conditionsModule":{"conditions":["Locally Advanced Cholangiocarcinoma","Intrahepatic Cholangiocarcinoma","Solid Tumor","Metastatic Cholangiocarcinoma"],"keywords":["FGFR2 gene activation","FGFR2 gene alterations","FGFR2 gene fusion/rearrangement","FGFR2 gene mutation","FGFR2 gene translocation","FGFR2","Fibroblast growth factor receptor 2 (FGFR2)","Fibroblast growth factor receptor 2 alterations","locally advanced cancer","metastatic cancer","solid tumors","cholangiocarcinoma","intrahepatic cholangiocarcinoma","unresectable cholangiocarcinoma","metastatic cholangiocarcinoma","fibroblast growth factor receptor inhibitor"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":40,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Phase 1 Part A and Part B","type":"EXPERIMENTAL","description":"TYRA-200 taken once daily by mouth in 28-day cycles","interventionNames":["Drug: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles","Drug: Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles"]}],"interventions":[{"type":"DRUG","name":"Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles","description":"TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.","armGroupLabels":["Phase 1 Part A and Part B"]},{"type":"DRUG","name":"Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles","description":"TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.","armGroupLabels":["Phase 1 Part A and Part B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Phase 1 Part A: To determine the maximum tolerated dose (MTD) of TYRA-200.","timeFrame":"Initiation of study treatment through 28 Days"},{"measure":"Phase 1 Part B: To determine the optimal dose of TYRA-200.","timeFrame":"Initiation of study treatment through 28 days (up to approximately 18 months"}],"secondaryOutcomes":[{"measure":"Number of participants with adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability.","timeFrame":"From day 1 treatment through 28-days post treatment (up to 2 years)"},{"measure":"Frequency in changes in laboratory parameters and physical signs of toxicity.","timeFrame":"From day 1 treatment through 28-days post treatment (up to 2 years)"},{"measure":"Pharmacokinetics: maximum plasma concentration (Cmax).","timeFrame":"From Day 1 through Cycle 3 Day 1 (each cycle is 28 days)"},{"measure":"Pharmacokinetics: time to reach maximum plasma concentration (Tmax).","timeFrame":"From Day 1 through Cycle 3 Day 1 (each cycle is 28 days)"},{"measure":"Pharmacokinetics: area under the plasma concentration-time curve (AUC).","timeFrame":"From Day 1 through Cycle 3 Day 1 (each cycle is 28 days)"},{"measure":"Pharmacokinetics: half-life of Tyra-200 (t1/2).","timeFrame":"From Day 1 through Cycle 3 Day 1 (each cycle is 28 days)"},{"measure":"Overall response rate (ORR) defined as the proportion of participants with complete response (CR) or partial response (PR) as determined by the investigator using RECIST V1.1.","timeFrame":"From enrollment, every 8 or 12 weeks (up to 2 years)"},{"measure":"Duration of response defined as the time from the initial CR or PR to the time of relapse or death, whichever occurs first among participant with an objective response.","timeFrame":"From enrollment, every 8 or 12 weeks (up to 5 years)"},{"measure":"Disease control rate defined as the proportion of participants having a CR, PR or stable disease (SD) for >12 weeks.","timeFrame":"From enrollment up to 5 years"},{"measure":"Time to response defined as time to first CR or PR that is subsequently confirmed according to RECIST v1.1.","timeFrame":"Up to 5 years"},{"measure":"Progression-free survival defined as the time from the date of first study drug administration to the earliest date of documented disease progression or death.","timeFrame":"From the date of the first dose of study drug until disease progression or death as assessed up to the last efficacy assessment for disease progression (up to 5 years)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPhase 1 Part A\n\n* Men and women 18 years of age or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.\n* Any histologically confirmed advanced solid tumor with FGFR/FGF pathway alterations including FGFR gene mutations, fusions, and amplifications, as well as gene amplifications of FGFR ligands, who have exhausted or refused approved standard therapies.\n* Evaluable disease according to RECIST v1.1.\n\nPhase 1 Part B\n\n* Men and women 18 years of age or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.\n* Histologically confirmed locally advanced/metastatic intrahepatic cholangiocarcinoma with a previously identified FGFR2 gene mutation or rearrangement.\n* Must have received a prior FGFR inhibitor. Participants may have received more than 1 prior FGFR inhibitor.\n* Presence of an FGFR2 kinase domain mutation that confers resistance to previous/other FGFR inhibitors; resistance mutations should be identified by a US Food and Drug Administration authorized/approved companion diagnostic or a Clinical Laboratory Improvement Amendments (CLIA) validated local test performed in a certified laboratory.\n* At least 1 measurable lesion by RECIST v1.1.\n\nExclusion Criteria:\n\n* Discontinued a prior anti-FGFR therapy due to significant toxicity, defined as hepatotoxicity ≥Grade 3 or any Grade 4 toxicity according to CTCAE v5.0.\n* Has a serum phosphorus level \\> upper limit of normal (ULN) during screening that remains \\>ULN despite medical management.\n* Any ocular condition likely to increase the risk of eye toxicity.\n* History of or current uncontrolled cardiovascular disease.\n* Active, symptomatic, or untreated brain metastases.\n* Gastrointestinal disorders that will affect oral administration or absorption of TYRA-200.\n* Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Grace Indyk","role":"CONTACT","phone":"(619)728-4805","email":"TyraClinicalTrials@tyra.bio"}],"overallOfficials":[{"name":"Doug Warner","affiliation":"Tyra Biosciences, Inc","role":"STUDY_CHAIR"}],"locations":[{"facility":"University of California San Francisco (UCSF)","status":"RECRUITING","city":"San Francisco","state":"California","zip":"94143","country":"United States","contacts":[{"name":"Quincy Harris","role":"CONTACT","phone":"415-502-3310"}],"geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Massachusetts General Hospital","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","contacts":[{"name":"Haley Ellis, MD","role":"CONTACT","phone":"617-724-4000"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"The Ohio State University","status":"RECRUITING","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"The University of Texas MD Anderson Cancer Center","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77030","country":"United States","contacts":[{"name":"Jodi Rodon Ahnert, MD","role":"CONTACT","phone":"713-792-5603"}],"geoPoint":{"lat":29.76328,"lon":-95.36327}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D018281","term":"Cholangiocarcinoma"},{"id":"D000168","term":"Acrocephalosyndactylia"},{"id":"D009362","term":"Neoplasm Metastasis"}],"ancestors":[{"id":"D000230","term":"Adenocarcinoma"},{"id":"D002277","term":"Carcinoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D003398","term":"Craniosynostoses"},{"id":"D013580","term":"Synostosis"},{"id":"D004413","term":"Dysostoses"},{"id":"D001848","term":"Bone Diseases, Developmental"},{"id":"D001847","term":"Bone Diseases"},{"id":"D009140","term":"Musculoskeletal Diseases"},{"id":"D013576","term":"Syndactyly"},{"id":"D019465","term":"Craniofacial Abnormalities"},{"id":"D009139","term":"Musculoskeletal Abnormalities"},{"id":"D017880","term":"Limb Deformities, Congenital"},{"id":"D000013","term":"Congenital Abnormalities"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D009385","term":"Neoplastic Processes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false}
]}